-
My Account
In App
Open App
- Home
- My Feed
- Remove AdsGet Premium Content Go Pro @₹99
-
Elections 2024
-
IPL 2024
- FREE Credit Score₹100 Cash Reward
- Markets
- Web Stories
- Tax Calculator
- Forum
- Gold Rate
- Silver Rate
- Storyboard18
-
IPO
-
Economic Indicators
- Economic Calendar
- Global Markets
- US Markets
- Indian Indices
- News
-
Real Estate
- Big Shark Portfolios
- Portfolio
- Watchlist
- Personal Finance
-
Moneycontrol - SecureNow Health Insurance ratings
- Mutual Funds
- Currencies
- Cryptocurrency
- Media
- International
Cipla Ltd.
Sector: Pharmaceuticals & Drugs
Follow
Following
Cipla Ltd.
Sector:Pharmaceuticals & Drugs
Follow
Following
Day Range
1335.00
1357.70
L H
52 Week Range
896.30
1519.00
L H
Volume
1,173,025
*
Bid / Ask
* BSE Market Depth (19 Apr 2024)
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 5 | 1343.10 | 1344.05 | 26 |
| 39 | 1343.05 | 1346.00 | 30 |
| 166 | 1342.35 | 1347.50 | 1 |
| 12 | 1342.05 | 1350.00 | 26 |
| 3 | 1342.00 | 1352.00 | 240 |
| 0 | Total | Total | 0 |
0.00 / 0.00
Day Range
1335.35
1357.95
L H
52 Week Range
891.30
1519.00
L H
Volume
34,538
*
Bid / Ask
* BSE Market Depth (19 Apr 2024)
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 5 | 1343.10 | 1344.05 | 26 |
| 39 | 1343.05 | 1346.00 | 30 |
| 166 | 1342.35 | 1347.50 | 1 |
| 12 | 1342.05 | 1350.00 | 26 |
| 3 | 1342.00 | 1352.00 | 240 |
| 0 | Total | Total | 0 |
0.00 / 0.00
--
-- (--%)
As on --
Day Range
--
--
L H
Open Interest Analysis
Long Unwinding
(OI , PRICE )
Volume
--
Bid / Ask
/
--
-- (--%)
As on --
Day Range
--
--
L H
Moneyness
--
Volume
--
Bid / Ask
/
NSE
#KnowBeforeYouInvest
Note :Financial Information is based on consolidated numbers.
Note :Financial Information is based on consolidated numbers.
Note :Financial Information is based on consolidated numbers.
Note :Financial Information is based on consolidated numbers.
MC Essentials
75% Pass
MC Insights
Strong Performer
Stock with good financial performance alongside good to expensive valuation
Financials
Ownerships
Industry Comparison
Others
- Overview
- Chart
- Forecast
- MC Insights
- MC Technicals
- Scans
- Price & Volume
- News
- Forum
- Research
- Deals
- Insider
- Corp Action
- Financials
- Shareholding
-
| Open | 1,347.00 |
| Previous Close | 1,347.30 |
| Volume | 1,173,025.00 |
| Value (Lacs) | 15,785.98 |
| VWAP | 1,346.28 |
| Beta | |
| Mkt Cap (Rs. Cr.) | 108,655 |
| High | 1,357.70 |
| Low | 1,335.00 |
| UC Limit | 1,482.00 |
| LC Limit | 1,212.60 |
| 52 Week High | 1,519.00 |
| 52 Week Low | 896.30 |
| Face Value | 2.00 |
| All Time High | 1,519.00 |
| All Time Low | 44.89 |
| 20D Avg Volume | 1,550,967 |
| 20D Avg Delivery(%) | -- |
| Book Value Per Share | 289.93 |
| Dividend Yield | 0.63 |
| TTM EPS See historical trend | 45.88 (+40.36% YoY) |
| TTM PE See historical trend | 29.33 (Average PE) |
| P/B See historical trend | 4.65 (High P/B) |
| Sector PE | 54.32 |
Advanced Chart
Click here to expand*Delayed by 20 seconds.
Forecast
Share Price Forecast
Earnings Forecast
Valuations
Consensus Recommendations
- Buy
- Outperform
- Hold
- Underperform
- Sell
MC Insights
Strong Performer
Stock with good financial performance alongside good to expensive valuation
Get detailed analysis with Moneycontrol Stock Insights.
MC Technicals
TECHNICAL RATING
This represents current trend.
Click here for disclaimer.
Click here for disclaimer.
Trend
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
Pivot levels
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
Pivot levels
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
Moving Averages
| Days | |
|---|---|
| 5 | - - |
| 10 | - - |
| 20 | - - |
| 50 | - - |
| 100 | - - |
| 200 | - - |
TECHNICAL RATING
This
represents current trend.
Click here for disclaimer.
Click here for disclaimer.
Trend
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
Pivot levels
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
Pivot levels
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
Moving Averages
| Days |
|---|
TECHNICAL RATING
This
represents current trend.
Click here for disclaimer.
Click here for disclaimer.
Trend
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
Pivot levels
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
Pivot levels
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
Moving Averages
| Days |
|---|
Historical Rating
SCANS
Companies decreasing their Debt to Equity ratio
Companies that are decreasing efficiency in utilisation of Shareholders funds
Companies increasing efficiency in utilisation of all sources of capital
Companies that have grown profits and net profit margins over the past 12 months
Companies in which FIIs are reducing Holding
Book Value of these Companies Rising over last 3 Years
Powered by:
Price and Volume
Price Performance
| 1 Week | --% | |
| 1 Month | --% | |
| 3 Months | --% | |
| YTD | --% | |
| 1 Year | --% | |
| 3 Years | --% |
Volume Analysis
News
-
Hot Stocks: Here's why it's prudent to buy CDSL and sell Cipla for the short term Apr 15 2024 06:18 AM
-
Steady US sales to bring a healthy quarter for pharma sector Apr 10 2024 02:49 PM
-
Indian pharmaceutical market registers 9.5% growth in March Apr 08 2024 04:13 PM
-
US FDA's 6 observations for Cipla's Patalganga unit drags firm's shares down 1.5% Apr 05 2024 10:09 AM
Forum
Community Sentiments
Data not Available
-
a meeting of the board of directors of the company will be held on may 10, 2024, to consider and approve the standalone and consolidated audited financial results. View more
Posted by : kamal20
You will now receive notification when someone reply to this message.
Broker Research
REFINITIV Report
- Company analysis giving insights of fundamentals, earnings, relative valuations, risk, price momentum and inside trading.
- Thomson Reuters proprietary rating of stock on scale of 1 to 10
- Industry ranking and detailed sector analysis of recent happening in sector
- Analyst rating like Buy/Sell/Hold with Earnings estimates with 1 year price target
Deals
25 Jan, 2024
SOCIETE GENERALE
| Qty 1188318 | Price 1417.35 | % Traded 0.15 |
25 Jan, 2024
BNP PARIBAS ARBITRAGE
| Qty 1188318 | Price 1417.35 | % Traded 0.15 |
18 Jan, 2024
THE JUPITER GLOBAL FUND-JUPITER INDIA SELECT
| Qty 142206 | Price 1293.5 | % Traded 0.02 |
18 Jan, 2024
JUPITER SOUTH ASIA INVESTMENT COMPANY LIMITED
| Qty 142206 | Price 1293.5 | % Traded 0.02 |
14 Nov, 2022
ISHARES CORE MSCI EMERGING MARKETS ETF
| Qty 761176 | Price 1121.4 | % Traded 0.09 |
14 Nov, 2022
ISHARES CORE EMERGING MARKETS MAURITIUS CO
| Qty 761176 | Price 1121.4 | % Traded 0.09 |
03 Nov, 2022
ISHARES CORE MSCI EMERGING MARKETS ETF
| Qty 761176 | Price 1159.25 | % Traded 0.09 |
03 Nov, 2022
ISHARES CORE EMERGING MARKETS MAURITIUS CO
| Qty 761176 | Price 1159.25 | % Traded 0.09 |
*Transaction of a minimum quantity of 500,000 shares or a minimum value of Rs 5 crore.
15 Feb, 2022
Y K HAMIED
| Qty 13446504 | Price 910.05 | % Traded 1.67 |
15 Feb, 2022
M K HAMIED
| Qty 6723252 | Price 910.15 | % Traded 0.83 |
*A bulk deal is a trade where total quantity of shares bought or sold is more than 0.5% of the equity shares of a company listed on the exchange.
Insider Transaction Summary
18 Oct, 2023
Jaideep Mallick
Immediate Relative
| Qty 150 | Price 1269.8 | % Traded 0.00 | Post Tnx Hold. 0% |
18 Oct, 2023
Priyanka Mallick
Designated Person
| Qty 500 | Price 1273.28 | % Traded 0.00 | Post Tnx Hold. 0% |
18 Oct, 2023
Priyanka Mallick
Designated Person
| Qty 200 | Price 1186.67 | % Traded 0.00 | Post Tnx Hold. 0% |
13 Apr, 2023
Vidya Prabhakar Rote jointly with Kiran Rote
Designated Person
| Qty 1000 | Price 1075.9 | % Traded 0.00 | Post Tnx Hold. 0% |
13 Apr, 2023
Vidya Prabhakar Rote jointly with Kiran Rote
Designated Person
| Qty 1000 | Price 1110.38 | % Traded 0.00 | Post Tnx Hold. 0% |
13 Apr, 2023
Vidya Prabhakar Rote jointly with Kiran Rote
Designated Person
| Qty 1000 | Price 1119.15 | % Traded 0.00 | Post Tnx Hold. 0% |
*Disclosures under SEBI Prohibition of Insider Trading Regulations, 2015
15 Feb, 2022
Dr Y K Hamied & M K Hamied & PACs Disposal
Promoter
| Qty 20169756 | Price 0 | % Traded 2.50 | Post Tnx Hold. 34.23% |
12 Sep, 2021
Alps Remedies Pvt Ltd & M N Rajkumar Garments llp & PACs Disposal
Promoter
| Qty 5869837 | Price 0 | % Traded 0.73 | Post Tnx Hold. 36.73% |
21 Dec, 2020
ICICI Prudential Mutual Fund Disposal
Other
| Qty 673564 | Price 0 | % Traded 0.08 | Post Tnx Hold. 3.1% |
05 Mar, 2020
Life Insurance Corporation of India Acquisition
Other
| Qty 16294015 | Price 0 | % Traded 2.02 | Post Tnx Hold. 4.52% |
21 Jan, 2020
Mitsubishi UFJ Financial Group (MUFG) & PACs Disposal
Other
| Qty 16932277 | Price 0 | % Traded 2.10 | Post Tnx Hold. 3.46% |
13 Nov, 2019
Mitsubishi UFJ Financial Group (MUFG) & PACs Disposal
Other
| Qty 16787169 | Price 0 | % Traded 2.08 | Post Tnx Hold. 5.56% |
*Disclosures under SEBI SAST (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
Corporate Action
| Date | Agenda |
|---|
| Ex-Date | Type | Dividend (Rs) |
|---|
| Announcement Date | Ex-Bonus | Ratio |
|---|
| Ex-Split | Old FV | New FV |
|---|
| Ex-Right | Ratio | Premium |
|---|
| Date | Agenda |
|---|
Financials
PEERS
| Company Name | Price | % Chg | MCap(Cr) | TTM PE | P/B | ROE(%) | 1 Yr Perform(%) | Net Profit(Rs.) | Net Sales(Rs.) | Debt to Equity |
|---|---|---|---|---|---|---|---|---|---|---|
| Cipla | 1,345.75 | -0.12 | 108,655.18 | 29.33 | 4.64 | 11.96 | 47.58 | 2,835 | 22,753 | 0.02 |
| Sun Pharma | 1,522.80 | 0.42 | 365,370.73 | 41.02 | 6.52 | 15.13 | 52.97 | 8,560 | 43,885 | 0.11 |
| Dr Reddys Labs | 5,942.85 | -0.24 | 99,134.55 | 18.96 | 4.26 | 19.35 | 21.05 | 4,470 | 24,669 | 0.05 |
| Divis Labs | 3,671.70 | -1.00 | 97,472.10 | 70.47 | 7.63 | 14.28 | 9.85 | 1,823 | 7,767 | 0.00 |
| Mankind Pharma | 2,337.45 | -2.43 | 93,635.54 | 56.73 | 12.03 | 16.03 | - | 1,248 | 8,127 | 0.00 |
About the Company
Cipla Ltd focuses on the development of new formulations and has a wide range of pharmaceutical products. They offer prescription drugs, bulk drugs, animal products , pesticides, a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.The company offers drugs used for the treatment of cancer, Alzheimer`s, arthritis, Parkinsons, cardiovascular diesases,drugs that prevents transmission of AIDS from mother to child, provide consulting services on preparation of products and materials, conducts plant evaluation and supplies plant equipments. They have also recently launched a number of products like an oral emergency contraceptive pill under the brand name I-Pill, a breakthrough screening technology in India called the No Touch Breast Scan (NTBS); ` the first-ever painless, non-invasive and radiation-free breast scanning technique for detecting breast cancer at an early stage and a generic versions of anti-flu drugs oseltamivir and zanamivir in the local market to treat the H1N1 influenza.
Get more out of Moneycontrol, Go Pro!
-
Sharpest Opinions & Actionable Insights -
Exclusive Webinars -
Research & Expert Technical Analysis
